Roche To Buy Majority Stake In Tumor Diagnostic Company
The deal in which the Swiss pharmaceutical giant would acquire a majority of Foundation Medicine illustrates the growing importance of genetics diagnostics in the treatment of cancer. Meanwhile, hospital operator HCA Holdings Inc, said it would report better-than-expected 2014 results as a result of increased admissions and ER visits.
The Wall Street Journal:
Roche Holding To Pay $1.03 Billion For Diagnostics-Firm Stake
Roche Holding AG agreed to pay $1.03 billion for up to a 56.3% stake in Foundation Medicine Inc. in a collaboration that underscores the growing importance of genetic diagnostics in the treatment and development of drugs for cancer. (Winslow, 1/12)
The New York Times' Dealbook:
Roche To Buy Majority Stake In Foundation Medicine, Leader In Tumor Testing
The Swiss pharmaceutical giant Roche said on Monday that it would acquire a majority of the tumor-testing company Foundation Medicine for more than $1 billion, in a deal aimed at improving both cancer treatment and drug development. (Pollack, 1/12)
The Wall Street Journal:
HCA Holdings Says 2014 Results To Top Guidance
HCA Holdings Inc. said it would report better-than-expected 2014 results, bolstered by an increase in admissions and emergency room visits along with a one-time adjustment from Medicaid payments in Texas. The hospital operator said it now expects Ebitda for the year of $7.4 billion, topping its previous projection of $7.25 billion to $7.35 billion. (Armental, 1/9)
